Journal
FRONTIERS IN ONCOLOGY
Volume 11, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2021.666091
Keywords
acute myeloid leukemia; allogeneic stem cell transplantation; graft-vs-host disease; graft-vs-leukemia; chemotherapy; MRD (measurable residual disease)
Categories
Funding
- CRUK
- Cure Leukaemia
- Bloodwise
Ask authors/readers for more resources
AML is the most common indication for allo-SCT worldwide, with advancements in risk stratification, donor availability, and conditioning regimens expanding transplant access for high risk patients. Disease relapse remains the top cause of transplant failure, highlighting the need for novel strategies to reduce recurrence risk.
Acute Myeloid Leukemia (AML) is the commonest indication for allogeneic stem cell transplantation (allo-SCT) worldwide. The increasingly important role of allo-SCT in the management of AML has been underpinned by two important advances. Firstly, improvements in disease risk stratification utilizing genetic and Measurable Residual Disease (MRD) technologies permit ever more accurate identification of allo-mandatory patients who are at high risk of relapse if treated by chemotherapy alone. Secondly, increased donor availability coupled with the advent of reduced intensity conditioning (RIC) regimens has substantially expanded transplant access for patients with high risk AML In patients allografted for AML disease relapse continues to represent the commonest cause of transplant failure and the development of novel strategies with the potential to reduce disease recurrence represents a major unmet need.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available